All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Brexucabtagene autoleucel receives a positive opinion from EMA CHMP for the treatment of patients with R/R B-ALL
Bookmark this article
On July 22, 2022, it was announced that brexucabtagene autoleucel (brexu-cel) received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human use (CHMP) for the treatment of patients aged ≥26 years with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). The decision was based on results from an extended follow-up analysis of the ZUMA-3 trial (NCT02614066).1
The results, recently reported in the ALL Hub, demonstrated the durable efficacy and manageable safety profile of brexu-cel in adult patients with R/R B-ALL, with 71% achieving complete remission or complete remission with incomplete hematological recovery. The median overall survival was 25.4 months and no new safety signals were reported. These findings were consistent with the primary analysis.
Given the high treatment burden and low-survival rate of patients with R/R B-ALL, approval of brexu-cel marks a positive treatment advancement, and the first chimeric antigen receptor T-cell therapy approved, for this population of patients.
- Business Wire. Kite’s CAR T-cell therapy Tecartus® receives positive CHMP opinion in relapsed or refractory acute lymphoblastic leukemia (r/r ALL). https://www.businesswire.com/news/home/20220722005258/en/Kite%E2%80%99s-CAR-T-cell-Therapy-Tecartus%C2%AE-Receives-Positive-CHMP-Opinion-in-Relapsed-or-Refractory-Acute-Lymphoblastic-Leukemia-rr-ALL. Published Jul 22, 2022. Accessed Jul 25, 2022.
More about...
Your opinion matters
6 votes - 49 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox